-
摘要: 随着器官移植的高速发展，全球性器官短缺问题日益凸显。肝移植是目前治疗终末期肝病最有效的手段，但供者短缺一直是制约肝移植发展的关键问题，我国是乙型病毒性肝炎大国，供肝短缺问题尤为显著，很多危重症患者往往因为无法及时获得匹配的供肝，而失去最佳时机甚至死亡。ABO血型不相容（ABOi）肝移植作为一种扩大供者资源的策略，为那些等待合适供者的患者提供了新的希望。然而，由于ABOi肝移植术后更容易发生严重感染、抗体介导的排斥反应（AMR）、胆道并发症、血栓性微血管病以及急性肾损伤等并发症，因此备受争议。本文综述了ABOi肝移植的术前、术中和术后策略研究进展，旨在为ABOi肝移植临床应用及研究提供参考。Abstract: With rapid development of organ transplantation, the issue of global organ shortage has become increasingly prominent. At present, liver transplantation is the most effective treatment for end-stage liver disease. Nevertheless, the shortage of donors has been a key problem restricting the development of liver transplantation. China is a country with a larger number of hepatitis B, and the shortage of donor liver is particularly significant. Many critically ill patients often lose the best opportunity or even die because they cannot obtain a matched donor liver in time. As a strategy to expand the donor pool, ABO-incompatible (ABOi) liver transplantation offers new options for patients who are waiting for matched donors. However, ABOi liver transplantation is highly controversial due to higher risk of complications, such as severe infection, antibody-mediated rejection (AMR), biliary complications, thrombotic microangiopathy, and acute kidney injury, etc. In this article, research progress in preoperative, intraoperative and postoperative strategies of ABOi liver transplantation was reviewed, aiming to provide reference for clinical application and research of ABOi liver transplantation.
-
[1] HILL AL, KHAN M, KIANI AZ, et al. Global liver transplantation: emerging trends and ethical challenges[J]. Langenbecks Arch Surg, 2023, 408(1): 418. DOI: 10.1007/s00423-023-03144-4. [2] 朱志军. ABO血型不相容肝移植的免疫抑制策略[J]. 中国普外基础与临床杂志, 2021, 28(8): 981-986.ZHU ZJ. Immunosuppressive strategies for ABO-incompatible liver transplantation[J]. Chin J Bases Clin Gen Surg, 2021, 28(8): 981-986. [3] 韩环立, 戴小科, 李英存,等. ABO血型不相容儿童活体肝移植临床分析[J]. 四川大学学报(医学版), 2022, 53(5): 777-781.HAN HL, DAI XK, LI YC, et al. Clinical analysis of ABO-incompatible living-donor liver transplantation in children[J]. J Sichuan Univ (Med Sci), 2022, 53(5): 777-781. [4] JADAUN SS, SAIGAL S, AGARWAL S, et al. Practice of ABO-incompatible living donor liver transplant in India: an initial experience based on a survey[J]. J Clin Exp Hepatol, 2023, 13(5): 927-929. DOI: 10.1016/j.jceh.2023.04.007. [5] XIAO M, WAN Z, LIN X, et al. ABO-incompatible liver transplantation under the desensitization protocol with rituximab: effect on biliary microbiota and metabolites[J]. J Clin Med, 2022, 12(1): 141. DOI: 10.3390/jcm12010141. [6] EGAWA H, OIKE F, BUHLER L, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation[J]. Transplantation, 2004, 77(3): 403-411. DOI: 10.1097/01.TP.0000110295.88926.5C. [7] HONG SK, LEE KW, KIM JY, et al. Factors associated with rituximab-mediated B cell depletion in ABO-incompatible adult living donor liver transplantation[J]. Korean J Transplant, 2023, 37(3): 170-178. DOI: 10.4285/kjt.23.0031. [8] GAN K, LI Z, BAO S, et al. Clinical outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis[J]. Transpl Immunol, 2021, 69: 101476. DOI: 10.1016/j.trim.2021.101476. [9] CHENG CH, LEE CF, WANG YC, et al. ABO-incompatible liver transplantation: state of art and future perspectives[J]. Curr Pharm Des, 2020, 26(28): 3406-3417. DOI: 10.2174/1381612826666200506094539. [10] LEE J, KIM EJ, YANG SJ, et al. Impact of the baseline anti-A/B IgG titer on the clinical outcome in ABO-incompatible liver transplantation[J]. Transplantation, 2020, 104(S3): S526. DOI: 10.1097/01.tp.0000701344.29242.43. [11] SASAKI K, KOBAYASHI S, IWAGAMI Y, et al. Rituximab administration one week before ABO-incompatible liver transplantation due to drug-induced acute liver failure with hepatic coma: a case report[J]. Clin J Gastroenterol, 2023, 16(5): 709-714. DOI: 10.1007/s12328-023-01827-5. [12] HIRUKAWA K, SHINODA M, HASEGAWA Y, et al. Long-term outcomes following ABO-incompatible living donor liver transplantation for acute liver failure: a single-center experience of over 20 years[J]. Surg Today, 2023, 53(10): 1160-1172. DOI: 10.1007/s00595-023-02678-w. [13] KIM JM, KWON CH, JOH JW, et al. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor[J]. J Hepatol, 2013, 59(6): 1215-1222. DOI: 10.1016/j.jhep.2013.07.035. [14] MAKROO RN, AGRAWAL S, CHOWDHRY M, et al. Efficacy of single, extended and goal directed immunoadsorption in ABO incompatible living related donor liver transplantation[J]. Transfus Apher Sci, 2016, 55(3): 329-332. DOI: 10.1016/j.transci.2016.08.007. [15] USUI M, ISAJI S, MIZUNO S, et al. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation[J]. Clin Transplant, 2007, 21(1): 24-31. DOI: 10.1111/j.1399-0012.2006.00572.x. [16] MONTEIRO I, MCLOUGHLIN LM, FISHER A, et al. Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation[J]. Transplantation, 2003, 76(11): 1648-1649. DOI: 10.1097/01.TP.0000082723.02477.87. [17] EGAWA H, UMESHITA K, UEMOTO S. Optimal dosage regimen for rituximab in ABO-incompatible living donor liver transplantation[J]. J Hepatobiliary Pancreat Sci, 2017, 24(2): 89-94. DOI: 10.1002/jhbp.419. [18] EGAWA H. Challenge to ABO blood type barrier in living donor liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 342-348. DOI: 10.1016/j.hbpd.2020.06.017. [19] JADAUN SS, AGARWAL S, GUPTA S, et al. Strategies for ABO incompatible liver transplantation[J]. J Clin Exp Hepatol, 2023, 13(4): 698-706. DOI: 10.1016/j.jceh.2022.12.008. [20] IKEGAMI T, TAKETOMI A, SOEJIMA Y, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation[J]. Transplantation, 2009, 88(3): 303-307. DOI: 10.1097/TP.0b013e3181adcae6. [21] KIM SH, LEE EC, SHIM JR, et al. A simplified protocol using rituximab and immunoglobulin for ABO-incompatible low-titre living donor liver transplantation[J]. Liver Int, 2018, 38(5): 932-939. DOI: 10.1111/liv.13614. [22] JOHN GT, JACOB CK, SUNDARAM M, et al. The first ABO incompatible kidney transplantation without splenectomy in India - a review at 12 years[J]. Indian J Nephrol, 2023, 33(3): 234-236. DOI: 10.4103/ijn.ijn_295_21. [23] TANABE M, KAWACHI S, OBARA H, et al. Current progress in ABO-incompatible liver transplantation[J]. Eur J Clin Invest, 2010, 40(10): 943-949. DOI: 10.1111/j.1365-2362.2010.02339.x. [24] RAUT V, UEMOTO S. Management of ABO-incompatible living-donor liver transplantation: past and present trends[J]. Surg Today, 2011, 41(3): 317-322. DOI: 10.1007/s00595-010-4437-3. [25] OH J, KIM JM. Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation[J]. Clin Mol Hepatol, 2020, 26(1): 1-6. DOI: 10.3350/cmh.2019.0023. [26] EGAWA H, OHDAN H, SAITO K. Current status of ABO-incompatible liver transplantation[J]. Transplantation, 2023, 107(2): 313-325. DOI: 10.1097/TP.0000000000004250. [27] 曲伟, 朱志军, 魏林,等. Rituximab+IVIG方案预防儿童ABO血型不相容肝移植血型抗体介导排斥反应效果的临床研究[J]. 中国普外基础与临床杂志, 2021, 28(8): 987-991.QU W, ZHU ZJ, WEI L , et al. Clinical research of effect of rituximab +IVIG regimen to prevent pediatric ABO incompatible living donor liver transplantation[J]. Clin J Bases Clin Gen Surg, 2021, 28(8): 987-991. [28] MOON DB, LEE SG, KANG WH, et al. Adult living donor liver transplantation for acute-on-chronic liver failure in high-model for end-stage liver disease score patients[J]. Am J Transplant, 2017, 17(7): 1833-1842. DOI: 10.1111/ajt.14198. [29] SKOGSBERG DAHLGREN U, HERLENIUS G, GUSTAFSSON B, et al. Excellent outcome following emergency deceased donor ABO-incompatible liver transplantation using rituximab and antigen specific immunoadsorption[J]. Scand J Gastroenterol, 2022, 57(1): 50-59. DOI: 10.1080/00365521.2021.1976269. [30] LEE WC, CHENG CH, LEE CF, et al. Quick preparation of ABO-incompatible living donor liver transplantation for acute liver failure[J]. Clin Transplant, 2022, 36(3): e14555. DOI: 10.1111/ctr.14555. [31] MYSORE KR, HIMES RW, RANA A, et al. ABO-incompatible deceased donor pediatric liver transplantation: novel titer-based management protocol and outcomes[J]. Pediatr Transplant, 2018, 22(7): e13263. DOI: 10.1111/petr.13263. [32] LEMOINE CP, BRANDT KA, KESWANI M, et al. Outcomes after ABO incompatible pediatric liver transplantation are comparable to ABO identical/compatible transplant[J]. Front Pediatr, 2023, 11: 1092412. DOI: 10.3389/fped.2023.1092412. [33] LEE TB, KO HJ, SHIM JR, et al. ABO-incompatible living donor liver transplantation with a simplified desensitization and immunosuppression protocol: a single-center retrospective study[J]. Exp Clin Transplant, 2021, 19(7): 676-685. DOI: 10.6002/ect.2021.0025. [34] PERRY DK, BURNS JM, POLLINGER HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production[J]. Am J Transplant, 2009, 9(1): 201-209. DOI: 10.1111/j.1600-6143.2008.02461.x. [35] TAJIMA T, HATA K, OKAJIMA H, et al. Bortezomib against refractory antibody-mediated rejection after ABO-incompatible living-donor liver transplantation: dramatic effect in acute-phase?[J]. Transplant Direct, 2019, 5(10): e491. DOI: 10.1097/TXD.0000000000000932. [36] LEE WC, LEE CF, WU TH, et al. Clinical relevance of isoagglutinin rebound in adult ABO-incompatible living donor liver transplantation[J]. J Pers Med, 2021, 11(12): 1300. DOI: 10.3390/jpm11121300. [37] YANAGI Y, SAKAMOTO S, YAMADA M, et al. Acute antibody-mediated rejection coexisting with T cell-mediated rejection in pediatric ABO-incompatible transplantation[J]. Transplant Direct, 2022, 8(9): e1359. DOI: 10.1097/TXD.0000000000001359. [38] HAN CZ, WEI Q, YANG MF, et al. The critical role of therapeutic plasma exchange in ABO-incompatible liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(6): 538-542. DOI: 10.1016/j.hbpd.2022.06.019. -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 197
- HTML全文浏览量: 182
- PDF下载量: 43
- 被引次数: 0
